» Articles » PMID: 23331322

Macrophage-specific RNA Interference Targeting Via "click", Mannosylated Polymeric Micelles

Overview
Journal Mol Pharm
Specialty Pharmacology
Date 2013 Jan 22
PMID 23331322
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Macrophages represent an important therapeutic target, because their activity has been implicated in the progression of debilitating diseases such as cancer and atherosclerosis. In this work, we designed and characterized pH-responsive polymeric micelles that were mannosylated using "click" chemistry to achieve CD206 (mannose receptor)-targeted siRNA delivery. CD206 is primarily expressed on macrophages and dendritic cells and upregulated in tumor-associated macrophages, a potentially useful target for cancer therapy. The mannosylated nanoparticles improved the delivery of siRNA into primary macrophages by 4-fold relative to the delivery of a nontargeted version of the same carrier (p < 0.01). Further, treatment for 24 h with the mannose-targeted siRNA carriers achieved 87 ± 10% knockdown of a model gene in primary macrophages, a cell type that is typically difficult to transfect. Finally, these nanoparticles were also avidly recognized and internalized by human macrophages and facilitated the delivery of 13-fold more siRNA into these cells than into model breast cancer cell lines. We anticipate that these mannose receptor-targeted, endosomolytic siRNA delivery nanoparticles will become an enabling technology for targeting macrophage activity in various diseases, especially those in which CD206 is upregulated in macrophages present within the pathologic site. This work also establishes a generalizable platform that could be applied for "click" functionalization with other targeting ligands to direct siRNA delivery.

Citing Articles

Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.

Yang H, Li J, Song C, Li H, Luo Q, Chen M Int J Mol Sci. 2025; 26(4).

PMID: 40004206 PMC: 11855571. DOI: 10.3390/ijms26041743.


Organic Nanoparticles in Progressing Cardiovascular Disease Treatment and Diagnosis.

Udriste A, Burdusel A, Niculescu A, Radulescu M, Balaure P, Grumezescu A Polymers (Basel). 2024; 16(10).

PMID: 38794614 PMC: 11125450. DOI: 10.3390/polym16101421.


Mannose Ligands for Mannose Receptor Targeting.

Paurevic M, Srajer Gajdosik M, Ribic R Int J Mol Sci. 2024; 25(3).

PMID: 38338648 PMC: 10855088. DOI: 10.3390/ijms25031370.


Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.

Kang X, Huang Y, Wang H, Jadhav S, Yue Z, Tiwari A Pharmaceutics. 2024; 16(1).

PMID: 38258072 PMC: 10819517. DOI: 10.3390/pharmaceutics16010061.


In Vitro Targeted Delivery of Simvastatin and Niacin to Macrophages Using Mannan-Grafted Magnetite Nanoparticles.

Rastegari B, Talepoor A, Khosropanah S, Doroudchi M ACS Omega. 2024; 9(1):658-674.

PMID: 38222576 PMC: 10785661. DOI: 10.1021/acsomega.3c06389.


References
1.
Connelly L, Jacobs A, Palacios-Callender M, Moncada S, Hobbs A . Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem. 2003; 278(29):26480-7. DOI: 10.1074/jbc.M302238200. View

2.
Vasievich E, Huang L . The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm. 2011; 8(3):635-41. PMC: 5514373. DOI: 10.1021/mp1004228. View

3.
Convertine A, Benoit D, Duvall C, Hoffman A, Stayton P . Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release. 2008; 133(3):221-9. PMC: 3110267. DOI: 10.1016/j.jconrel.2008.10.004. View

4.
Pollard J . Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008; 84(3):623-30. PMC: 2516896. DOI: 10.1189/jlb.1107762. View

5.
Yu S, Ortega R, Reagan B, McPherson J, Sung H, Giorgio T . Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011; 3(6):620-46. PMC: 5486233. DOI: 10.1002/wnan.158. View